P2RY2
P2Y purinoceptor 2
As of the edition of 20 October 2026, P2RY2 (P2Y purinoceptor 2, UniProt P41231) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P41231
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Eye; Lungs and airways; Digestive system; Inherited and neonatal; Ear, nose and throat; Immune system
- Registered trials of its drugs
- 44
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Diquafosol | Marketed | Phase 4 | none listed |
| Denufosol | Stopped | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Undetermined | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Santen Pharmaceutical | Route B |
The other 1 company at P2RY2
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at P2RY2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.